The pendulum appears to be swinging towards vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) with immune checkpoint inhibitors (ICIs) for the front-line treatment of metastatic renal cell carcinoma (mRCC).
L. Meza
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with L.
Contact L., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack